NASDAQ:AIMT - Aimmune Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $33.06
  • Forecasted Upside: -4.14 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 7 Hold Ratings
  • 2 Buy Ratings
  • 0 Strong Buy Ratings
$34.49
+0.30 (1.20%)
Get New Aimmune Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AIMT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AIMT

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$33.06
▼ -4.14% Downside Potential
This price target is based on 9 analysts offering 12 month price targets for Aimmune Therapeutics in the last 3 months. The average price target is $33.06, with a high forecast of $58.00 and a low forecast of $15.00. The average price target represents a -4.14% upside from the last price of $34.49.
Hold
The current consensus among 9 contributing investment analysts is to hold stock in Aimmune Therapeutics. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 5 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 3 buy ratings
  • 5 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 7 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 8 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
1/28/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings
2/27/2021

Latest Recommendations

  • 0 strong buy ratings
  • 2 buy ratings
  • 7 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/1/2020Credit Suisse GroupBoost Price TargetNeutral$14.00 ➝ $34.50Low
i
9/1/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$24.00 ➝ $35.00Low
i
Rating by C. Duncan at Cantor Fitzgerald
8/31/2020WedbushDowngradeOutperform ➝ Neutral$66.00 ➝ $34.50Low
i
Rating by Liana Moussatos at Wedbush
8/31/2020Piper SandlerDowngradeOverweight ➝ Neutral$60.00 ➝ $34.50N/A
i
8/3/2020WedbushReiterated RatingBuy$66.00Medium
i
Rating by Liana Moussatos at Wedbush
7/31/2020Cantor FitzgeraldLower Price Target$32.00 ➝ $24.00High
i
7/30/2020Stifel NicolausReiterated RatingHold$18.00High
i
Rating by Derek Archila at Stifel Nicolaus
7/29/2020Credit Suisse GroupLower Price TargetNeutral$19.00 ➝ $15.00Low
i
7/13/2020CowenInitiated CoverageOutperform$35.00Medium
i
5/13/2020WedbushReiterated RatingBuy$66.00High
i
Rating by Liana Moussatos at Wedbush
5/13/2020Credit Suisse GroupLower Price TargetNeutral$29.00 ➝ $19.00High
i
Rating by Evan Seigerman at Credit Suisse Group AG
5/12/2020HC WainwrightLower Price TargetNeutral$30.00 ➝ $15.00Medium
i
Rating by A. Fein at HC Wainwright
5/11/2020Stifel NicolausReiterated RatingHold$32.00 ➝ $20.00Low
i
Rating by Derek Archila at Stifel Nicolaus
3/23/2020Cantor FitzgeraldLower Price TargetOverweight$64.00 ➝ $32.00High
i
3/18/2020WedbushReiterated RatingBuy$66.00Low
i
Rating by Liana Moussatos at Wedbush
3/18/2020JMP SecuritiesDowngradeOutperform ➝ Market PerformHigh
i
3/17/2020Robert W. BairdLower Price TargetOutperform$64.00 ➝ $58.00High
i
Rating by Brian Skorney at Robert W. Baird
3/3/2020WedbushReiterated RatingBuy$66.00N/A
i
Rating by Liana Moussatos at Wedbush
3/2/2020Credit Suisse GroupLower Price Target$34.00 ➝ $29.00High
i
Rating by Evan Seigerman at Credit Suisse Group AG
3/2/2020Stifel NicolausLower Price TargetHold$34.00 ➝ $32.00High
i
Rating by Derek Archila at Stifel Nicolaus
2/28/2020HC WainwrightReiterated RatingNeutral$33.00 ➝ $30.00Medium
i
Rating by A. Fein at HC Wainwright
2/26/2020WedbushReiterated RatingBuy$74.00Medium
i
Rating by Liana Moussatos at Wedbush
2/3/2020Robert W. BairdReiterated RatingBuy$64.00High
i
Rating by Brian Skorney at Robert W. Baird
2/3/2020WedbushBoost Price TargetOutperform$79.00 ➝ $81.00High
i
Rating by Liana Moussatos at Wedbush
2/3/2020JMP SecuritiesBoost Price TargetMarket Outperform$40.00 ➝ $44.00High
i
2/3/2020Cantor FitzgeraldBoost Price TargetOverweight$55.00 ➝ $64.00High
i
2/2/2020Stifel NicolausReiterated RatingHold$34.00High
i
Rating by Derek Archila at Stifel Nicolaus
1/23/2020Roth CapitalBoost Price Target$45.00 ➝ $50.00Medium
i
1/21/2020WedbushReiterated RatingBuy$79.00Medium
i
Rating by Liana Moussatos at Wedbush
1/9/2020WedbushReiterated RatingBuy$79.00Medium
i
Rating by Liana Moussatos at Wedbush
12/19/2019HC WainwrightInitiated CoverageNeutral$33.00Low
i
Rating by A. Fein at HC Wainwright
12/13/2019Credit Suisse GroupDowngradeOutperform ➝ Neutral$31.59 ➝ $30.00Medium
i
10/31/2019WedbushReiterated RatingBuyMedium
i
Rating by Liana Moussatos at Wedbush
10/25/2019The Goldman Sachs GroupSet Price TargetHold$27.00N/A
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
10/9/2019Piper Jaffray CompaniesSet Price TargetBuy$60.00N/A
i
Rating by Christopher Raymond at Piper Jaffray Companies
9/16/2019WedbushReiterated RatingHold ➝ Outperform$79.00Medium
i
Rating by Liana Moussatos at Wedbush
9/16/2019Stifel NicolausUpgradePositiveHigh
i
9/11/2019Stifel NicolausBoost Price TargetHold$24.00 ➝ $30.00High
i
8/21/2019WedbushSet Price TargetBuy$79.00High
i
Rating by Liana Moussatos at Wedbush
8/18/2019Stifel NicolausReiterated RatingHold$24.00High
i
8/9/2019Royal Bank of CanadaLower Price TargetOutperform$50.00Medium
i
7/12/2019Roth CapitalInitiated CoverageBuy ➝ Buy$45.00Low
i
Rating by Z. Jallah at Roth Capital
7/11/2019WedbushSet Price TargetBuy$79.00Medium
i
Rating by Liana Moussatos at Wedbush
7/2/2019WedbushReiterated RatingBuy$79.00Low
i
Rating by Liana Moussatos at Wedbush
6/6/2019WedbushReiterated RatingOutperform$79.00Medium
i
Rating by Liana Moussatos at Wedbush
5/24/2019WedbushSet Price TargetBuy$79.00Low
i
Rating by Liana Moussatos at Wedbush
5/21/2019Credit Suisse GroupInitiated CoverageOutperform$36.00 ➝ $30.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
5/9/2019WedbushReiterated RatingBuy$79.00Low
i
Rating by Liana Moussatos at Wedbush
5/9/2019Cantor FitzgeraldReiterated RatingBuy$45.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
4/11/2019Cantor FitzgeraldReiterated RatingBuyMedium
i
Rating by Charles Duncan at Cantor Fitzgerald
3/26/2019WedbushSet Price TargetBuy$79.00Medium
i
Rating by Liana Moussatos at Wedbush
3/19/2019WedbushLower Price TargetOutperform$80.00 ➝ $76.00High
i
Rating by Liana Moussatos at Wedbush
3/7/2019WedbushReiterated RatingBuy$80.00Low
i
Rating by Liana Moussatos at Wedbush
2/28/2019Cantor FitzgeraldSet Price TargetBuy$45.00Medium
i
Rating by Charles Duncan at Cantor Fitzgerald
2/26/2019WedbushReiterated RatingBuy$80.00Medium
i
Rating by Liana Moussatos at Wedbush
2/5/2019WedbushReiterated RatingOutperform$80.00High
i
Rating by Liana Moussatos at Wedbush
1/15/2019Credit Suisse GroupReiterated RatingBuy$40.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
12/20/2018The Goldman Sachs GroupSet Price TargetHold$36.00High
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
12/13/2018WedbushSet Price TargetBuy$80.00Low
i
Rating by Liana Moussatos at Wedbush
12/13/2018Roth CapitalSet Price TargetBuy$80.00High
i
Rating by Jotin Marango at Roth Capital
12/13/2018Cantor FitzgeraldSet Price TargetBuy$64.00High
i
Rating by Charles Duncan at Cantor Fitzgerald
12/13/2018The Goldman Sachs GroupInitiated CoverageNeutral ➝ Neutral$32.00High
i
Rating by Paul Choi at The Goldman Sachs Group, Inc.
12/12/2018Credit Suisse GroupSet Price TargetBuy$40.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
12/9/2018Cantor FitzgeraldInitiated CoverageOverweight$64.00 ➝ $23.75Low
i
Rating by Charles Duncan at Cantor Fitzgerald
12/2/2018Cantor FitzgeraldInitiated CoverageBuy$64.00Low
i
Rating by C. Duncan at Cantor Fitzgerald
11/23/2018Cantor FitzgeraldReiterated RatingOverweightLow
i
Rating by C. Duncan at Cantor Fitzgerald
11/19/2018Credit Suisse GroupSet Price TargetBuy$40.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
11/19/2018Roth CapitalSet Price TargetBuy$80.00High
i
Rating by Jotin Marango at Roth Capital
11/12/2018WedbushSet Price TargetBuy$80.00Low
i
Rating by Liana Moussatos at Wedbush
11/12/2018Cantor FitzgeraldSet Price TargetBuy$62.00Low
i
Rating by William Tanner at Cantor Fitzgerald
11/11/2018Stifel NicolausSet Price TargetHold$33.00High
i
Rating by Derek Archila at Stifel Nicolaus
11/11/2018Roth CapitalSet Price TargetBuy$80.00High
i
Rating by Jotin Marango at Roth Capital
11/9/2018Credit Suisse GroupSet Price TargetBuy$40.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
10/17/2018WedbushInitiated CoverageBuy$72.00High
i
Rating by Liana Moussatos at Wedbush
10/15/2018Cantor FitzgeraldSet Price TargetBuy$62.00Low
i
Rating by William Tanner at Cantor Fitzgerald
10/9/2018Roth CapitalSet Price TargetBuy$80.00Low
i
Rating by Jotin Marango at Roth Capital
9/13/2018Stifel NicolausInitiated CoverageHold$33.00High
i
8/13/2018Credit Suisse GroupSet Price TargetOutperform ➝ Buy$47.00 ➝ $40.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
6/12/2018Credit Suisse GroupSet Price TargetBuy$47.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
5/30/2018WedbushReiterated RatingOutperform$72.00Low
i
Rating by L. Moussatos at Wedbush
5/18/2018Piper Jaffray CompaniesInitiated CoverageOverweight$60.00 ➝ $30.01High
i
Rating by Charles Duncan at Piper Jaffray Companies
5/10/2018Credit Suisse GroupSet Price TargetBuy$47.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
5/10/2018WedbushReiterated RatingOutperform$72.00Medium
i
Rating by L. Moussatos at Wedbush
5/9/2018Cantor FitzgeraldReiterated RatingBuy$64.00High
i
Rating by W. Tanner at Cantor Fitzgerald
4/5/2018Piper Jaffray CompaniesSet Price TargetBuy$62.00Low
i
Rating by Charles Duncan at Piper Jaffray Companies
3/6/2018WedbushReiterated RatingOutperform$72.00High
i
Rating by L. Moussatos at Wedbush
3/5/2018Credit Suisse GroupSet Price TargetOutperform ➝ Buy$45.00 ➝ $47.00Medium
i
Rating by Vamil Divan at Credit Suisse Group AG
3/5/2018Roth CapitalBoost Price TargetBuy$75.00 ➝ $80.00Low
i
Rating by J. Marango at Roth Capital
3/5/2018Cantor FitzgeraldReiterated RatingOverweight$64.00Low
i
Rating by W. Tanner at Cantor Fitzgerald
2/27/2018Royal Bank of CanadaBoost Price TargetOutperform$62.00Medium
i
2/27/2018Piper Jaffray CompaniesSet Price TargetBuy$62.00Low
i
Rating by Charles Duncan at Piper Jaffray Companies
2/27/2018Credit Suisse GroupSet Price TargetBuy$45.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
2/23/2018WedbushReiterated RatingBuyLow
i
Rating by L. Moussatos at Wedbush
2/20/2018Deutsche Bank AktiengesellschaftSet Price TargetBuy$30.00High
i
Rating by Andrew Peters at Deutsche Bank Aktiengesellschaft
2/20/2018Credit Suisse GroupSet Price TargetBuy$45.00High
i
Rating by Vamil Divan at Credit Suisse Group AG
2/20/2018Cantor FitzgeraldReiterated RatingBuyHigh
i
Rating by W. Tanner at Cantor Fitzgerald
2/12/2018WedbushReiterated RatingOutperformLow
i
Rating by L. Moussatos at Wedbush
2/7/2018Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$55.00High
i
1/31/2018Roth CapitalBoost Price TargetBuy$60.00 ➝ $75.00Medium
i
Rating by J. Marango at Roth Capital
1/11/2018Credit Suisse GroupSet Price TargetBuy$45.00Low
i
Rating by Vamil Divan at Credit Suisse Group AG
12/20/2017Robert W. BairdInitiated CoverageOutperform ➝ Outperform$64.00Medium
i
12/12/2017Cantor FitzgeraldInitiated CoverageOverweight$55.00High
i
Rating by W. Tanner at Cantor Fitzgerald
12/5/2017Piper Jaffray CompaniesBoost Price TargetOverweight$38.00 ➝ $60.00Low
i
Rating by Charles Duncan at Piper Jaffray Companies
12/1/2017WedbushReiterated RatingOutperform$70.00Low
i
11/20/2017Roth CapitalInitiated CoverageBuy ➝ Buy$60.00N/A
i
Rating by Jotin Marango at Roth Capital
10/23/2017Credit Suisse GroupBoost Price TargetOutperform$36.00 ➝ $45.00N/A
i
10/23/2017WedbushReiterated RatingOutperform$42.00 ➝ $70.00N/A
i
10/21/2017Piper Jaffray CompaniesSet Price TargetBuy$38.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
8/14/2017WedbushReiterated RatingOurperform$42.00Low
i
7/27/2017Piper Jaffray CompaniesSet Price TargetBuy$38.00Low
i
Rating by Charles Duncan at Piper Jaffray Companies
7/24/2017WedbushReiterated RatingOutperform$42.00Medium
i
3/22/2017Piper Jaffray CompaniesReiterated RatingOverweight$38.00Low
i
3/15/2017Piper Jaffray CompaniesLower Price Target$38.00High
i
3/11/2017Piper Jaffray CompaniesBoost Price TargetOverweight$40.00N/A
i
2/19/2017Piper Jaffray CompaniesReiterated RatingOverweight$40.00N/A
i
2/17/2017WedbushReiterated RatingOutperform$42.00N/A
i
2/13/2017Piper Jaffray CompaniesReiterated RatingOverweight$40.00N/A
i
2/8/2017WedbushReiterated RatingOutperform$42.00N/A
i
12/2/2016WedbushReiterated RatingOutperform$42.00N/A
i
11/18/2016Piper Jaffray CompaniesReiterated RatingOverweight$38.00 ➝ $40.00N/A
i
11/10/2016WedbushReiterated RatingOutperform$42.00N/A
i
9/26/2016JMP SecuritiesInitiated CoverageOutperform$30.00N/A
i
9/23/2016Piper Jaffray CompaniesReiterated RatingOverweight$38.00N/A
i
9/21/2016WedbushReiterated RatingOutperform$42.00N/A
i
8/24/2016WedbushReiterated RatingBuy$42.00N/A
i
Rating by Liana Moussatos at Wedbush
8/19/2016Credit Suisse GroupReiterated RatingBuy$35.00N/A
i
8/10/2016WedbushReiterated RatingOutperform$42.00N/A
i
Rating by Liana Moussatos at Wedbush
6/29/2016Piper Jaffray CompaniesReiterated RatingOverweight$38.00N/A
i
6/14/2016Piper Jaffray CompaniesReiterated RatingOverweight$38.00N/A
i
6/13/2016WedbushReiterated RatingOutperform$42.00N/A
i
Rating by Liana Moussatos at Wedbush
5/17/2016Piper Jaffray CompaniesReiterated RatingOverweight$38.00N/A
i
5/16/2016Bank of AmericaReiterated RatingBuyN/A
i
Rating by Ying Huang at Bank of America Co.
5/16/2016WedbushReiterated RatingOutperform$42.00N/A
i
Rating by Liana Moussatos at Wedbush
4/12/2016Piper Jaffray CompaniesReiterated RatingOverweight$38.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
3/7/2016Credit Suisse GroupLower Price TargetOutperform$44.00 ➝ $35.00N/A
i
3/6/2016WedbushReiterated RatingBuy$42.00N/A
i
Rating by Liana Moussatos at Wedbush
2/29/2016WedbushInitiated CoverageOutperform$42.00N/A
i
Rating by L. Moussatos at Wedbush
2/29/2016Piper Jaffray CompaniesReiterated RatingOverweight$38.00N/A
i
Rating by Charles Duncan at Piper Jaffray Companies
(Data available from 2/28/2016 forward)
Aimmune Therapeutics logo
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow's milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.
Read More

Today's Range

Now: $34.49
$34.49
$34.49

50 Day Range

MA: $34.46
$34.30
$34.59

52 Week Range

Now: $34.49
$10.09
$37.00

Volume

N/A

Average Volume

1,714,599 shs

Market Capitalization

$2.26 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.76

Frequently Asked Questions

What sell-side analysts currently cover shares of Aimmune Therapeutics?

The following Wall Street research analysts have issued research reports on Aimmune Therapeutics in the last twelve months: Cantor Fitzgerald, Cowen Inc, Credit Suisse Group AG, HC Wainwright, JMP Securities, Piper Sandler, Robert W. Baird, Stifel Nicolaus, Wedbush, and Zacks Investment Research.
View the latest analyst ratings for AIMT.

What is the current price target for Aimmune Therapeutics?

8 Wall Street analysts have set twelve-month price targets for Aimmune Therapeutics in the last year. Their average twelve-month price target is $33.06, suggesting a possible downside of 4.1%. Robert W. Baird has the highest price target set, predicting AIMT will reach $58.00 in the next twelve months. HC Wainwright has the lowest price target set, forecasting a price of $15.00 for Aimmune Therapeutics in the next year.
View the latest price targets for AIMT.

What is the current consensus analyst rating for Aimmune Therapeutics?

Aimmune Therapeutics currently has 7 hold ratings and 2 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in AIMT, but not buy more shares or sell existing shares.
View the latest ratings for AIMT.

What other companies compete with Aimmune Therapeutics?

How do I contact Aimmune Therapeutics' investor relations team?

Aimmune Therapeutics' physical mailing address is 8000 MARINA BOULEVARD SUITE 300, BRISBANE CA, 94005. The biotechnology company's listed phone number is 650-614-5220 and its investor relations email address is [email protected] The official website for Aimmune Therapeutics is www.aimmune.com.